Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 268 of 6351
-
New hope for rectal cancer: extra chemo may save the rectum
Disease control CompletedStandard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase quality of …
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can a new drug pair tame hodgkin lymphoma in older patients?
Disease control CompletedTreatment outcome with ABVD in elderly patients remains inferior to adults. Moreover, Bleomycin-induced lung toxicity in the elderly has been reported as high as 46%. For these reasons, questions arise whether ABVD could be still considered the standard treatment in HL patients a…
Phase 1/2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Immunotherapy combo tested for tough lung cancer
Disease control OngoingThis randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a …
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New vaccine aims to shield transplant patients from deadly virus
Vaccine OngoingThis randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients previously infected with CMV and are undergoing a donor hematopoietic cell transplant. CMV is …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Vaccine
Last updated Jul 30, 2026 00:00 UTC
-
Could a third drug boost melanoma immunotherapy?
Disease control OngoingThis phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread fr…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New immune drug aims to keep lung cancer away after surgery
Disease control OngoingThis is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New stroke clot removal technique could boost recovery rates
Disease control CompletedMechanical thrombectomy (TM) is now validated through 4 randomized controlled trials of high scientific level as the reference treatment of cerebral infarction associated with proximal cerebral occlusion (MR CLEAN, ESCAPE 2014, 2015). These studies have shown for the first time a…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can an oral chemo pill boost immunotherapy's power against lung cancer?
Disease control Stopped earlyThe purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cance…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThe Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including prur…
Phase 2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktails aim to tackle tough myeloma
Disease control Recruiting nowThis study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). Th…
Phase 1/2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Which hormone drug best halts lobular breast cancer growth?
Disease control CompletedRATIONALE: Currently, adjuvant endocrine therapy often follows a "one-size-fits- all" approach, with most premenopausal women receiving tamoxifen, and most postmenopausal receiving aromatase inhibitor therapy. In current clinical practice, patients with invasive lobular carcinoma…
Phase 2 • Sponsor: Priscilla McAuliffe • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Keytruda plus radiation shows promise against lung cancer
Disease control CompletedThis randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation therapy) and to see how well they work in treating patien…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to wipe out hidden leukemia cells before they return
Disease control CompletedThis phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Personalized vaccine plus chemo cocktail aims to outsmart advanced ovarian cancer
Disease control CancelledThis study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a cocktail …
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise against CLL
Disease control OngoingThis phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has returned (relapsed), does not respond to treatment (ref…
Phase 1/2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a second round of pertuzumab help fight advanced breast cancer?
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer patients for previously treated with pertuzumab
Phase 3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC
-
Can engineered immune cells target a common ovarian cancer protein?
Disease control OngoingThe purpose of this phase I study is to test the safety of different dose levels of specially prepared cells collected called "modified T cells". In the screening part of this study the tumor was found to have a protein called MUC16. This protein is present on about 70% of ovaria…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New CLL drug acalabrutinib takes on ibrutinib in Head-to-Head trial
Disease control OngoingThis study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
Phase 3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could adding carboplatin to chemo keep triple-negative breast cancer away?
Disease control OngoingThis randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclopho…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New triple therapy targets hard-to-treat breast cancers
Disease control OngoingStudy combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
Phase 1/2 • Sponsor: Priyanka Sharma • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC